Skip to main content
Fig. 6 | Breast Cancer Research

Fig. 6

From: Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers

Fig. 6

Mass spectrometry-based DIA analyses identified unique pathways modulated by ERX-11+palbociclib combination therapy. MCF-7/TamR cells were treated with E2 (10−8 M) in the presence or absence of ERX-11(1 μM), palbociclib (0.25 μM), or ERX-11+palbociclib for 72 h. a Venn diagram showing differentially expressed proteins ≥ 1.5-fold difference (either up or down) among the groups. b Scaffold DIA results for GAPDH and Ki-67 (protein data in the table and representative fragment intensities displayed underneath)

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us